EVO
Evotec SE ADR
Healthcare · ·
$2.80
Data: 2026-06-03
✓ ETHICAL PASS

NONE MOAT
LIMITED
Data Confidence: 0.0%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$1.0B
Total market value of the company
Trailing P/E
N/A
Forward P/E
-15.37
Based on estimated future earnings — lower means cheaper
Rev Growth
-21.7%
Year-over-year revenue change
Profit Margin
-26.0%
How much profit the company keeps from each dollar of revenue
ROE
-24.1%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$5.43
+94% from current price — median analyst estimate
Recommendation
NONE
Consensus view from 4 analysts covering this stock
About Evotec SE ADR

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is

https://www.evotec.com

Country: Germany Employees: 4,526 Industry: Drug Manufacturers - Specialty & Generic
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.0% PENDING
Debt must be below 33% of total assets
Cash Ratio
0.0% PENDING
Interest-bearing cash below 33% of assets
Receivables
0.0% PENDING
Receivables below 49% of assets
Revenue Purity
0.0% PENDING
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
MARKDOWN
Price trending down — defensive positioning
Sharpe Ratio
-0.066
Returns do not compensate for the risk — negative edge
Kelly Fraction
-0.0357
No positive edge detected — the data suggests staying out
Calmar Ratio
-0.388
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-22.7%
Historical annualised return based on price data
Max Drawdown
-58.4%
Largest peak-to-trough decline — the worst it has been
HMM State
BULL
Statistical model sees bullish momentum
Days in State
36
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
1.30
Moves slightly more than the broader market
52W High
$4.44
37% below the year high
52W Low
$2.31
21% above the year low
Avg Volume
101,079
Average daily shares traded — higher means easier to buy and sell
Short Ratio
0.6
Days it would take all short sellers to cover — higher means more crowded
Short % Float
N/A
Div Yield
N/A
Annual dividend as a percentage of the share price
EPS (TTM)
$-0.63
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
55.38
Heavy leverage — higher financial risk if revenues decline
Current Ratio
N/A
Quick Ratio
N/A
Like current ratio but excludes inventory — stricter test
Gross Margin
10.7%
Revenue left after cost of goods — higher means pricing power
Operating Margin
-29.6%
Profit from core operations before interest and tax
Free Cash Flow
$99M
Positive — the business generates more cash than it spends
Revenue (TTM)
$745M
Total revenue over the last 12 months
Net Income
$-193,876,000
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
4
Target High
$6.91
Target Median
$5.43
Target Low
$2.96
Political Trading Activity

Congressional trading disclosures involving this instrument

Date Politician Party Type Amount
8 May2026 Kevin Hern Republican exchange 15K–50K
8 May2026 Kevin Hern Republican exchange 15K–50K
Source: Congressional disclosure filings. View all political trades at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.